PRESS RELEASE



Sanofi Provides an Update on its Research & Development Pipeline Paris, France - January 8, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) today will provide an update on its Research & Development (R&D) pipeline with Dr. Elias Zerhouni, President, Global Research and Development, presenting at the JP Morgan Healthcare Conference in San Francisco, California.

Highlights of the presentation will include key products in late stage development in several disease areas with significant development and regulatory milestones in the next six months. Executing a successful strategy to reposition Sanofi R&D has fueled a pipeline with 65 NME (New Molecular Entity) projects and vaccine candidates in clinical development of which 17 are in Phase III or have been submitted to the health authorities for approval.

"Sanofi has made significant progress in the transformation of its R&D over the last couple of years, including advances in late stage projects and early stage pipeline as well as talent recruitment. We feel we have the ingredients to ensure R&D contributes to Sanofi's goal of sustainable growth in the coming years while rigorously managing R&D costs," said Dr. Elias Zerhouni.

Regarding regulatory milestones, Sanofi received two positive opinions from the Committee for Medicinal Products for Human Use (CHMP) since the last R&D update on October 25, 2012, with decisions from the European Commission targeted in Q1 2013: Lyxumia® (lixisenatide) in type 2 diabetes and Zaltrap® (aflibercept) in metastatic second-line colorectal cancer.

Portfolio update